Thioredoxin Reductase 1 Expression and Castration-recurrent Growth of Prostate Cancer.
BACKGROUND
Many genes are differentially expressed between androgen-dependent and androgen-independent prostate cancer (CaP). Differential expression analysis and subtractive hybridization previously identified nine genes expressed in intact mice bearing CWR22 tumors and castrated mice bearing recurrent CWR22 tumors but not in regressed tumors. The objectives of this study were to develop an immunostaining method to dual-label foci of proliferating tumor cells [the origin of castration-recurrent CaP (CR-CaP)], to determine which of the nine candidate proteins were differentially expressed in proliferating versus nonproliferating cells at the onset of growth after castration, and to test preclinical findings using clinical specimens of androgen-stimulated benign prostate (AS-BP) and CaP (AS-CaP) and CR-CaP.


METHODS
Paraffin-embedded, bromodeoxyuridine-injected CWR22 tumors were hydrated, antigen-retrieved using high heat and high pressure, labeled for each of the nine antigens of interest, visualized using peroxidase, and counterstained with hematoxylin. Mean optical density was calculated for proliferating and nonproliferating areas using automated (nuclear staining) or manual (cytoplasmic staining) image analysis. Prostate tissue microarray sections were immunostained and visually scored.


RESULTS
Immunohistochemistry revealed higher nuclear expression of thioredoxin reductase 1 (TrxR1) in proliferating cells than nonproliferating cells (P < .005). There were no statistical differences between cell types in the expression of other proteins. TrxR1 expression was higher (P < .01) in CR-CaP compared with AS-BP or AS-CaP.


CONCLUSIONS
Increased TrxR1 expression in CR-CaP was consistent with increased TrxR1 and BrdU expression at the onset of growth in the CWR22 model. Thioredoxin reductase 1 should be targeted in an attempt to delay or prevent CaP recurrence after castration.
Singh
Swaroop S
SS
Department of Urologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA.
Li
Yun
Y
Ford
Oscar Harris
OH
Wrzosek
Carol S
CS
Mehedint
Diana C
DC
Titus
Mark A
MA
Mohler
James L
JL
J Urol. 1998 Mar;159(3):641-9
9474117
Prostate. 2002 Jun 1;51(4):247-55
11987153
Histochem J. 2002 Mar-Apr;34(3-4):97-103
12495214
Appl Immunohistochem Mol Morphol. 2002 Sep;10(3):263-8
12373155
Arch Immunol Ther Exp (Warsz). 2001;49(4):285-92
11726031
J Cell Biochem. 2005 Oct 15;96(3):653-64
16088946
J Androl. 2001 Jul-Aug;22(4):537-48
11451350
Semin Cancer Biol. 2006 Dec;16(6):420-6
17092741
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
J Histochem Cytochem. 2002 Aug;50(8):1005-11
12133903
Clin Cancer Res. 2001 Oct;7(10):3087-91
11595699
Cancer Res. 1998 Dec 15;58(24):5718-24
9865729
Cancer Biol Ther. 2005 Jan;4(1):6-13
15684606
Cytometry. 1999 Jan 1;35(1):2-10
10554175
Cancer Lett. 2006 May 8;236(1):46-53
15982805
J Lab Clin Med. 2003 Jul;142(1):46-51
12878985
Cancer Res. 1996 Jul 1;56(13):3042-6
8674060
Endocrinology. 1993 Jan;132(1):169-78
8419121
Pancreas. 2008 Mar;36(2):178-86
18376310
Mol Endocrinol. 1997 Apr;11(4):450-9
9092797
J Histochem Cytochem. 2001 Aug;49(8):931-7
11457921
Am J Pathol. 2002 Jan;160(1):219-26
11786415
J Biol Chem. 1999 Sep 24;274(39):27891-7
10488136
Cancer Res. 1994 Dec 1;54(23):6049-52
7525052
J Natl Cancer Inst. 1993 Mar 3;85(5):394-8
8433392
PLoS One. 2007 Oct 31;2(10):e1112
17971875
Endocrinology. 1988 Feb;122(2):552-62
2828003
Eur J Biochem. 2000 Oct;267(20):6102-9
11012661